"I feel privileged to work in a stimulating and collaborative environment as part of an organization that strives to provide meaningful treatment of human disease."
I joined the Protein Chemistry Department at Genentech in 2002 after completing a post-doctoral fellowship at Stanford University. At that time, and today, Genentech places tremendous value on collaborations between the therapeutic areas and technology groups like Protein Chemistry to facilitate the development of novel therapeutics. Currently, my group is focused on the development of novel molecules for indications in cancer immunotherapy and treatments of neurodegenerative diseases.
The postdoctoral program at Genentech is essential maintaining cutting edge basic and translational research. Post-doctoral projects at the company often lay the ground work for new therapeutic target or alternatively, can help us understand the mechanism of action of existing therapeutics. Post-doctoral projects in my lab focus cell and tissue pentation properties of large or small molecules and the interaction of antibodies with Fc receptors.
J Biol Chem. 2017 Mar 3;292(9):3900-3908.
EBioMedicine. 2015 May 30;2(7):730-43.
My group develops large molecules, antibodies and engineered proteins, as therapeutics. Recently our work has focused not only on identification of therapeutic antibody candidates, but also on selective delivery of therapeutics to specific organs or tissues. One exciting outcome of a collaborative research effort with Genentech neuroscience has been the discovery of novel blood brain barrier engineered antibodies. Another engineering example is our work with the metabolic disease group to selectively activate receptors to improve glucose uptake in target tissues. More recently, my group has added a focus on antibody effector function, Fc receptor interaction and antibody endothelial cell recycling.
Identification of a potential therapeutic often proceeds hand-in-hand with efforts to understand the molecular role of the drug target in disease. To better understand the function of the amyloid protein Abeta and Tau in Alzheimer's disease, my group is studying the aggregation properties of these proteins and is working with the neurodegeneration department to understand how aggregation of Abeta and Tau spread throughout the brain and impacts neuronal death.